Company Overview

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted radiotherapies for hematologic malignancies and certain solid tumor indications. The company operates within the biotechnology and oncology sectors, with a primary emphasis on antibody-radioconjugates and radiotherapy conditioning agents used prior to bone marrow transplantation or cellular therapies. Its core strategy centers on delivering radioactive isotopes directly to cancer cells through monoclonal antibodies, with the objective of improving efficacy while limiting systemic toxicity.

The company’s principal development programs include Iomab-B, an iodine-131-based radiotherapeutic conditioning agent intended for patients with relapsed or refractory acute myeloid leukemia undergoing bone marrow transplant, and Actimab-A, a CD33-targeting radiotherapy candidate being evaluated in combination with other therapeutic regimens. Actinium has also expanded into alpha-particle radiotherapy platforms through actinium-225-based technologies. Founded in 2000 and headquartered in New York, New York, the company evolved from early-stage radiopharmaceutical research into a publicly traded oncology-focused developer listed on the NYSE American under the ticker ATNM.

Business Operations

Actinium generates its business activity primarily through the research, development, and clinical advancement of targeted radiotherapies. The company does not currently report commercial product revenue and remains principally funded through equity offerings, licensing arrangements, and strategic collaborations. Its lead business activities are organized around proprietary radiopharmaceutical platforms, including the Iomab platform and the Actimab program. These programs combine radioisotopes such as iodine-131 and actinium-225 with monoclonal antibodies designed to selectively target cancer-associated antigens including CD33 and CD45.

The company’s operations are primarily based in the United States, though its clinical trial activity and research collaborations extend internationally. Actinium has entered partnerships with academic cancer centers, isotope suppliers, and biotechnology companies to support clinical development and isotope access. The company has disclosed collaborations involving cell therapy and transplant-focused institutions, including partnerships intended to evaluate radiotherapy conditioning alongside CAR-T and other cellular therapies. Actinium also maintains intellectual property related to radioconjugate manufacturing, isotope delivery, and targeted conditioning technologies.

Strategic Position & Investments

Actinium’s strategic direction is centered on expanding the use of targeted radiotherapy in hematologic cancers and conditioning regimens for stem cell transplantation and cell-based therapies. A major focus has been the advancement of Iomab-B, including regulatory engagement following the pivotal SIERRA trial in older patients with relapsed or refractory acute myeloid leukemia. The company has positioned the therapy as a potential alternative to conventional conditioning regimens that may be poorly tolerated in elderly or medically fragile patients.

In addition to late-stage development efforts, Actinium has invested in earlier-stage alpha-emitter technologies involving actinium-225 and other isotopes with potential applications in precision oncology. The company has pursued licensing and supply arrangements to secure access to radioisotopes and has expanded research collaborations intended to support combination approaches with immunotherapies and cellular therapies. Actinium has also highlighted opportunities in targeted conditioning for gene-editing and transplant applications, reflecting broader industry interest in radiopharmaceutical-based preparative regimens.

Geographic Footprint

Actinium Pharmaceuticals is headquartered in New York, New York, and its principal operational footprint is concentrated in the United States. Clinical development activities are conducted through collaborations with major cancer treatment centers and transplant institutions across North America. The company’s regulatory and investor activities are also U.S.-focused due to its public listing and clinical trial infrastructure.

Although the company does not maintain the same commercial global footprint as large multinational pharmaceutical companies, it participates in international oncology and radiopharmaceutical networks through isotope sourcing, scientific collaborations, and clinical engagement. Its technologies are relevant to transplant and oncology markets in North America, Europe, and select international regions where radiopharmaceutical infrastructure and hematologic cancer treatment capabilities are established.

Leadership & Governance

Actinium Pharmaceuticals is led by executives with backgrounds in biotechnology, oncology development, capital markets, and radiopharmaceutical commercialization. The company’s leadership has emphasized advancing targeted radiotherapies through clinical validation, regulatory engagement, and strategic partnerships in transplant medicine and precision oncology.

Key executives and leadership figures include:

• Sandesh Seth – Chairman and Chief Executive Officer
• Stephen O'Loughlin, M.D. – Principal Medical Advisor
• David Nicholson – Chief Financial Officer
• Mark Berger, M.D. – Chief Medical Officer
• Sam Berridge – Executive Vice President, Head of Strategy and Business Development

The company’s governance structure includes a board with experience in oncology, biotechnology financing, and pharmaceutical development. Public disclosures, including filings such as SEC Form 10-K and investor presentations, indicate that management’s strategic priorities include advancing late-stage clinical programs, expanding radiopharmaceutical platform applications, and pursuing partnerships that may accelerate commercialization opportunities.